Akums Drugs Posts Rs 234 Crore Profit in FY25
By Ankur Chandra | Updated at: May 31, 2025 10:41 PM IST
Akums Drugs and Pharmaceuticals Ltd, India’s largest contract development and manufacturing organization (CDMO), registered a robust performance during Q4 and full year FY25, with growth in revenues, strategic capex, and a strong order pipeline to support its global expansion plan.
Key Financial Highlights
| ₹ in Cr | Q4 FY25 | Q3 FY25 | Q4 FY24 | FY25 | FY24 |
|---|---|---|---|---|---|
| Revenue | 1,056 | 1,010 | 944 | 4,118 | 4,178 |
| Other Income | 18 | 15 | 10 | 52 | 34 |
| Total Income | 1,073 | 1,025 | 954 | 4,170 | 4,212 |
| COGS | 639 | 602 | 569 | 2,433 | 2,550 |
| Employee Cost | 184 | 176 | 164 | 716 | 647 |
| Other Expenses | 139 | 111 | 128 | 508 | 500 |
| Adj. EBITDA | 111 | 136 | 98 | 513 | 515 |
| EBITDA Margin (%) | 10.4% | 13.3% | 10.3% | 12.3% | 12.2% |
| Adj. PAT | 44 | 66 | 46 | 234 | 220 |
| PAT Margin (%) | 4.1% | 6.5% | 4.8% | 5.6% | 5.2% |
- Q4 revenue rose 12.4% YoY to ₹1,073 crore, with adjusted EBITDA of ₹111 crore.
- FY25 PAT improved to ₹234 crore from ₹220 crore in FY24, despite muted revenue due to API price erosion.
Management Commentary
Mr Sanjeev Jain, Chief Managing Director, “Our first step into Europe marks a major phase in Akums’ global CDMO growth. Through strategic capacity expansions and laser-focused on differentiated offerings, we are well-positioned to be your trusted global manufacturing partner.”
Sandeep Jain, Managing Director, said: “Given API price pressure and industry uncertainty, Akums ended FY25 on a high. Our new injectable manufacturing plant is up and running, our R&D pipeline is maturing, and our product portfolio is gaining traction with partners.”
Future Outlook
Akums continues to prioritize innovation, operational excellence, and international expansion. With a firm footing in India’s CDMO space and a growing presence in Europe, the company is focused on capturing long-term growth opportunities and delivering shareholder value. Akums Drugs and Pharmaceuticals Ltd. is a leading CDMO with a robust portfolio of pharmaceutical formulations, serving clients across global regulated markets. The company is ISO, WHO-GMP, and NSF certified, and operates multiple state-of-the-art facilities across India.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.
REF: https://nsearchives.nseindia.com/corporate/NSEAKUMS10_26052025194237_AKUMSPRESSRELEASE.pdf
